SPECT/CT Imaging of Skeletal Muscle Perfusion

Overseen By Albert J. Sinusas, MD

Age: 18+

Sex: Any

Trial Phase: Academic

Sponsor: Yale University

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: Unknown

140 Participants Needed

Trial Summary

What is the purpose of this trial?

This study will use SPECT/CT imaging to assess the effect of percutaneous revascularization treatments in patients with Peripheral arterial disease and diabetes mellitus, in whom the disease can progress more quickly than in patients without diabetes.

Research Team

Albert J. Sinusas, MD

Principal Investigator

Yale University

Eligibility Criteria

Inclusion Criteria

This is not a screening criterion, but rather a section heading. It likely refers to the group of participants who will not receive the study drug (i.e. the control group).

Sorry, this criterion is unclear and incomplete. Can you please provide more context or information?

Tests show that you have significant blockages in the arteries of your legs.

Treatment Details

Interventions

• SPECT/CT Imaging

Participant Groups

Group I: Participants with PAD Experimental Treatment 1 Intervention

Subjects will undergo resting perfusion imaging of the feet using two separate SPECT/CT systems. Subjects will be injected with a low dose radioisotope. Heated venous blood sampling will be obtained.

Group II: Controls Experimental Treatment 1 Intervention

Subjects will undergo resting perfusion imaging of the feet using two separate SPECT/CT systems. Subjects will be injected with a low dose radioisotope. In addition to heated venous blood sampling, arterial blood will be continuously sampled from the radial artery for calculation of a blood input function and K1 values for foot angiosomes.

Who Is Running the Clinical Trial?

Yale University

Lead Sponsor

Trials

1,963

Recruited

3,046,000+

University of Illinois at Urbana-Champaign

Collaborator

Trials

203

Recruited

40,600+